Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir Plus Glecaprevir/Pibrentasvir in Chronic HCV Treatment-naïve Patients With Early Liver Disease
NCT03855917Phase 4Recruiting
- Sponsor
- The Kirby Institute
- Start
- Feb 2020
- Primary completion
- Jul 2029
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sofosbuvir, glecaprevir and pibrentasvir in hepatitis C (HCV), sponsored by The Kirby Institute. Primary endpoint: Sustained Virologic Response at 12 weeks. Started Feb 2020; status: recruiting.
02
Drugs
sofosbuvirglecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03855917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855917.